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S Cyclophosphamide, a drug that has not 
ummCH"Y • 1 had· 1 . preVIOUS y an unportant ro e ill 
whole-organ transplantation, was given as a primary 
immunosuppressant to one liver and eleven kidney 
recipients, in combination with prednisone and horse 
antilymphocyte globulin. One of the patients died 
despite good renal-graft function. Two kidneys from 
a common cadaveric donor failed. The other nine 
patients have excellent function of their homografts 
after 2-3 months. Cyclophosphamide was substituted 
for azathioprine in one hepatic and five renal recipients 
who were suspected of having liver toxicity from 
azathioprine 3 months to almost 8 years post-trans-
plantation. Graft function was maintained after this 
change, and the evidence of liver injury subsided. 
INTRODUCTION 
SINCE its clinical introduction in 1962, azathioprine 
has been considered the cornerstone agent in both the 
double-drug 1-0 and triple-drug 6 immunosuppressive 
regimens that have received worldwide trial. In the 
first regimen azathioprine was given with prednisone 
and in the second it was combined with prednisone and 
heterologous antilymphocyte globulin (A.L.G.). 
We have shown azathioprine to be dispensable by 
replacing it from the beginning with cyclophosphamide 
in twelve organ recipients who were managed in other 
respects by the triple-drug programme. In addition, 
six patients who were treated at first with azathioprine 
and who were suspected of having hepatoxicity from this 
agent had cyclophosphamide substituted from 3 
months to almost 8 years after renal (five cases) or 
liver (one case) transplantation. 
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Although the follow-ups are still short, we are con-
vinced that cyclophosphamide is a major neglected 
immunosuppressant--one that is at least as potent and 
practical as azathioprine for whole-organ transplantation 
and one that may permit substantial improvements 
in patient care. 
METHODS 
Cyclophosphamide from Outset 
Using standard surgical techniques,6,7 eleven patients 
received kidney grafts and one was given an orthotopic 
liver for the indications listed in table I. Three of the 
eleven renal patients were undergoing transplantation for 
the second time after rejecting their first kidneys hyper-
acutely (case 10), acutely (case 2), or by a chronic process 
(case 3), despite therapy with the old triple-drug regimen 
that included azathioprine. A fourth renal patient (case 6) 
hyperacutely rejected a maternal homograft oiuting treat-
ment with the cyclophosphamide-containing triple-drug 
programme. The transplant was immediately removed. 
The recipient had performed cytotoxic antibodies against 
the mother's lymphocytes but not against those of the 
cadaver, which donated a functioning kidney II days later. 
Cadaveric organs provided the definitive homografts in 
eight of the twelve cases. Within this group of donor/ 
recipient pairs there were no good HL-A matches-indeed 
a "full house" mismatch was either proved or else possible 
in half of these cases. When the transplanted organ 
came from a relative the quality of matching ranged from 
excellent to poor. A sutnmary grade (table I) of the tissue 
match was given by the A-D, F designations of Terasaki 
and colleagues,8 the A-D spectrum going from the best to 
the worst compatibility, and the F denoting a positive 
cross-match. 
The treatment schedule was adapted from the triple-drug 
regimen used at our institution since 1966, except that 
cyclophosphamide was administered in place of azathio-
prine. The patients receiving consanguineous kidneys 
were given cyclophosphamide orally for 4-9 days before 
operation (average 5'3), starting with 1·4-2·1 mg. per kg. 
per day and concluding with loading doses the day before 
and the day of transplantation of 2'45-5·8 mg. per kg. per 
day. During the same pretreatment interval daily intra-
muscular injections were given of horse A.L.G. that had 
leucoagglutinin and lymphocytotoxin titres of 1/8000 and 
1116,000, respectively, and a protein concentration of 5'1-
7·2 g. per 100 m!. Finally, prednisone was started orally in 
preoperative doses of 0·6-0'7 mg. per kg. per day. A 
typical schedule of treatment for intrafamilial cases is 
shown in fig. 1. 
For the cadaveric cases, pretreatment was not feasible, 
and immunosuppression was usually started on the day of 
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Fig. i-A moderately severe but completely reversed rejection crisis 10 days after 
renal transplantation from a sibling to an HL-A matched recipient who was treated 
with cyclophosphamide, prednisone, and A.L.G. 
B.U.N. =Blood-urea-nitrogen. Ccr = Creatinine clearance. 
W.B.C. = White-blood-cell count. 
operation. Under these conditions (fig. 2), the initial dose 
of cyclophosphamide was 1·0-4·8 mg. per kg. by intravenous 
infusion over 3 hours, usually during the operation. 
After transplantation, drug therapy was by the general 
triple-drug format previously described,s·7 except that 
cyclophosphamide instead of azathioprine was used (figs. 1 
and 2). The protocol called for a decreasing number of 
A.L.G. injections after 2 weeks and for adjustments in 
prednisone dosage, especially after the first few weeks, 
according to the difficulty encountered with rejection. 
The average daily doses of cyclophosphamide used post-
operatively were usually slightly more than 1 mg. per kg. 
per day (table I). These doses were adjusted carefully, a 
primary objective being the avoidance of leucopenia 
(figs. 1 and 2). If for any reason the patient was not eating, 
the cyclophosphamide or prednisone was switched from 
the oral to the intravenous route. 
Late Cyclophosphamide Substitution 
Renal recipients.-Five renal recipients had liver-function 
abnormalities consisting most prominently in four cases of 
elevated S.G.O.T. and S.G.P.T. These four recipients were 
not jaundiced, but the fifth patient had become deeply 
BUN 
(mgIlOOml) 
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PREDNISONE 
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Fi&,. 2--Case 2: uncomplicated early course of the recipient of a 
c:adaveric kidney. 
icteric (bilirubin 13 mg. per 100 m!.) and was approaching 
the terminal stages of liver disease. Multiple sera from the 
five recipients were studied by three precipitation methods 
as well as by complement-fixation to determine if the 
Australia (Au) antigen was or had ever been detectable in 
the postoperative period. Evidence of the Au antigen was 
present in only one of the cases. In all five, it was considered 
that azathioprine hepatotoxicity was a possible factor. 
Consequently, azathioprine was stopped from 3 months 
to almost 8 years post-transplantation (table II) and cyclo-
phosphamide was substituted at comparable doses per kg. 
Hepatic and renal function were monitored both before 
and after this change. 
Hepatic recipient.-Cyclophosphamide was substituted 
for azathioprine in the recipient of an orthotopic liver 
homograft who had persistent transaminase elevations 
many months after operation (see Results). 
RESULTS 
Cyclophosphamide from Outset 
Mortality.-One of the twelve patients (case 3) 
died 62 days after retransplantation. In January, 1969, 
she had received a cadaveric kidney which slowly failed 
6 
TABLE II-S.G.O.T. IN FIVE RENAL HOMOGRAFT RECIPIENTS DURING 
TREATMENT WITH AZATHIOPRINE AND CYCLOPHOSPHAMIDE, 
RESPECTIVELY (THE MEAN VALUES ARE GIVEN OF 2-5 DETERMINA-
TIONS BEFORE AND AFTER THE CHANGE) 
S.G.O.T. (I.U.) during 
Case Time of change treatment with: 
no. post-transplantation eycio-Azathioprine phosphamide 
1 10 mo. 256 312 
2 7 yr., 9 mo. 425 62 
3 Smo. 142 105 
4 3 yr., 3 mo. 607 193 
5' 3 mo. 91 22 
. . 
• Au-anURen posluve. 
over the ensuing 2 years, the blood-urea-nitrogen 
eventually rising to about 100 mg. per 100 ml. Under 
cyclophosphamide/prednisone/A.L.G. treatment, a sec-
ond cadaveric kidney was placed on the other side 
without removal of the first transplant. Despite the 
sparing use of prednisone, there was no rejection. 
However, the patient's condition deteriorated with a 
very severe herpes-zoster infection of the perineum 
which was made almost unmanageable by intractable 
diarrhcea. At necropsy, a giant ulcer of the crecum and 
ascending colon was found, involving most of the 
bowel circUInference and causing transmural necrosis. 
Both transplanted kidneys were examined by Prof. 
K. A. Porter, of St. Mary's Hospital and Medical 
School, London. The first homograft had a fresh 
thrombosis of the renal artery with multiple cortical 
infarctions. The renal homograft which had been 
protected by the new immunosuppressive regimen 
was almost normal. The only abnormalities were a 
light, scattered infiltration with mononuclear cells 
and atrophy of a few tubules. 
Graft 10ss.-The hyperacutely rejected maternal 
kidney will not be mentioned further in this report 
since it was immediately removed and could not be 
considered for the evaluation of treatment. Of the 
twelve definitive organs, there were two renal homo-
grafts, both from the same cadaveric donor, which 
failed. One of these organs (case 4) never functioned 
well and was unable to reduce the blood-urea-nitrogen 
below 64 mg. per 100 ml. during the first 5 post-
operative weeks. A second cadaveric kidney was then 
placed on the other side without removal of the first 
one, with excellent function during the ensuing 6 
weeks. A recent intravenous pyelogram displayed 
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the second transplant but not the first one. The contra-
lateral kidney from the same donor had fair initial 
function (case 5) which first improved and later deterior-
ated so that return to dialysis was necessary 9!-
weeks after transplantation. 
Rejection.-There was no evidence of rejection of 
seven of the twelve organs that have been followed up 
for 2 months or longer; these included six kidneys 
(fig. 2) and the liver. Two other homografts (cases 
6 and 8) underwent equivocal rejection for which 
minor steroid adjustments were made. One patient, 
who was given a kidney by her sister with whom she 
had a perfect HL-A match, had a severe rejection 
crisis which was completely reversed (fig. 1). 
The liver recipient had a completely uncomplicated 
recovery at first, but 6 weeks after operation jaundice 
developed, and serum transaminases and aIkaline-
phosphatase levels rose. Coincident with these changes, 
the complement-fixation test for Au antigen became 
positive with a titre of 1/5000. The findings of hepatitis 
subsequently receded. 
Graft functien.-The kidneys and liver remaining 
all have normal or nearly normal function after 2 to 
more than 3 months. 
Toxicity.-Most cases have had no evidence of bone-
marrow depression at any time (figs. 1 and 2). How-
ever, three of the twelve patients had significant 
leucopenia as defined by the need to omit cyclo-
phosphamide for at least 3 consecutive days. There 
was only one example of leucopenia for as long as a 
week. Thrombocytopenia was occasionally seen, but it 
seemed related more to A.L.G. therapy than to cyclo-
phosphamide. Some of the classical complications of 
cyclophosphamide therapy were never observed, 
including hremorrhagic cystitis and alopecia. Early 
in the series, cyclophosphamide was given orally 
in the early evening, some time after the evening meal. 
Anorexia, nausea, vomiting, and diarrh~ were 
common. However, when the medication was given 
with the evening meal, these symptoms were avoided 
in all but case 3. At necropsy, the explanation for the 
intractable diarrhrea in this patient was a giant crecal 
and right colonic ulcer. 
Late Cyclophosphamide Substitution 
Renal recipients.-Renal recipients (cases 2-5, 
table II), who had elevated serum-transaminases as the 
predominant finding of post-transplantation liver 
600 
500 
400 
SGOT 300 
(I.U.) 
200 
100 
75 
8 
50+-----------------____ __ 
mg/day 25 AZATHIOPRINE 
iii i , , iii i 
140 160 180 200 220 240 260 280 300 320 
DAYS POST - TRANSPLANT AT ION 
Fig. 3-S.G.O.T. values (normal range 4-13 I.U.) in a patient 
who received an orthotopic liver homograft 9 months previ-
ously; azathioprine wa. replaced by cyclophosphamide. 
after the change to cyclophosphamide. In the fifth 
patient (case 1, table II), with hepatic failure and 
jaundice, the raised transaminase levels did not 
improved immediately; however, the serum-bilirubin 
slowly fell from 13 mg. per 100 ml. to normal and she 
eventually recovered completely. In all five recipients, 
renal homograft function remained unchanged or else 
improved after the change to cyclophosphamide. 
Hepatic recipient.-This patient had undergone 
liver replacement 7 months earlier for the treatment of 
chronic aggressive hepatitis, Au-antigen positive. 
Au antigen disappeared for almost 2 months but then 
reappeared. At the same time, all hepatic-function 
tests deteriorated. The problem was diagnosed and 
treated as acute hepatitis. Many of the manifestations 
of the serum-hepatitis, including jaundice, subsided, 
but the Au antigen remained positive and there were 
persistent deviations of S.G.O.T. and S.G.P.T. Mter 
substitution of cyclophosphamide for azathioprine, 
because of the suspicion of drug hepatotoxicity, the 
transaminase values promptly fell (fig. 3) despite 
continuing Au antigenlEmia. 
DISCUSSION 
Until now, consistent recovery after whole-organ 
9 
transplantation in man has been well documented only 
with drug regimens that included azathioprine. In 
this investigation, cyclophosphamide replaced azathio-
prine, and was given in combination with prednisone 
and horse A.L.G. The cyclophosphamide doses per 
kg. were smaller than those that would have been pre-
dicted for azathioprine, but they were similar enough, 
so that the substitution of cyclophosphamide for 
azathioprine required little mental adjustment. 
We looked for the well-known adverse reactions of 
cyclophosphamide seen in cancer chemotherapy-
including alopecia, bone-marrow depression, and 
serious gastrointestinal disturbances. In the dose 
range used, these toxic effects were generally either not 
troublesome or not observed at all. In one patient, a 
crecal ulcer was the most important factor in causing 
death, but this kind of complication'has been seen with 
all steroid-containing immunosuppressive regimens. 
Leucopenia, presumably from bone-marrow depres-
sion, was observed in only three patients, and it was a 
transient finding that did not necessitate prolonged 
withdrawal of cyclophosphamide treatment. 
The results of therapy with this triple-drug pro-
gramme have been so encouraging that we believe that 
cyclophosphamide should make possible major im-
provements in the care of organ-transplant recipients. 
Rejection has never been diagnosed in seven of the 
twelve redpients. It was of a very minor nature in 
two others and it was severe but completely reversible 
in one more. Two kidneys eventually failed, but under 
circumstances that may have been extenuating. Both 
these organs came from the same cadaver; one never 
functioned properly and the other provided acceptable 
function for a short time only. 
The success of treatment was especially striking since 
most of the cases were unfavourable by well-accepted 
criteria. Two-thirds of the organs were from cadavers; 
almost half of the recipients were relatively old; four 
of them were undergoing retransplantation with its 
risk of prior sensitisation; one was a liver recipient; 
and poor HL-A matches were present in nine of the 
twelve cases (although it must be conceded from our 
own experience that this is not necessarily an adverse 
factor 9). 
In retrospect, it is almost unbelievable that cyclo-
phosphamide has played such a trivial role in the trans-
plantation of whole human organs, since the drug has 
been thought for a decade to possess strong immuno-
-----.... -~K--
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suppressive properties. 10- 12 Moreover, the animal 
work in favour of this contention has been frequently 
reviewed and updated. I3- 19 Essentially all of the 
encouraging laboratory investigations were done in 
mice, rats or other rodents, or in rabbits. Unfortu-
nately, when cyclophosphamide was tested in the dog 
kidney or intestinal transplantation models as an 
intermediate step to clinical application; no prolonga-
tion of graft survival was obtained, or else the effect 
was a minor one. 20- 22 It may now be suggested that 
the dampening influence of the discouraging canine 
experiments was based upon a species difference that 
made the dog an inappropriate animal to evaluate 
cyclophosphamide for human immunosuppression. 
Despite the experience in dogs, there has been 
evidence in man supporting the propriety of testing 
cyclophosphamide for clinical whole-organ transplanta-
tion. Some of this information came from efforts to 
promote tolerance to bone-marrow grafts, as proposed 
by~pantos and colleagues 28,24 and subsequently carried 
out by several other workers. Prodigious doses of cyclo-
phosphamide (45-100 mg. per kg. per day) were given, 
but only for a few days in close temporal approximation 
to infusion of the homologous bone-marrow. Although 
such efforts represent an essentially different thera-
peutic approach to ours, it is worth emphasising that 
Santos' data on several immunosuppressive drugs have 
indicated that, in man, cyclophosphamide is superior 
to most other agents, including azathioprine. 23, 2. 
Immunosuppression with cyclophosphamide has 
been reported in a few cases of kidney transplantation. 
Almost 10 years ago Goodwin et al. treated a renal 
recipient with cyclophosphamide plus prednisone; 
good kidney function was maintained during much of 
the 144 days of post-transplantation life. 2. Shortly 
afterwards, Parsons, Fox, and others reported four cases 
of cadaveric renal transplantation in which cyclo-
phosphamide was given as the sole therapy. 1.," One 
patient died after a technical surgical accident, and a 
second died from infection after 33 days. The other 
two recipients lived for 8 and 23 months, a remarkable 
feat which in our experience can be achieved only rarely 
with azathioprine or any other single agent after 
renal transplantation from a non-relative. 6 In a follow-
up of these two patients, and four more who survived 
for only a few days, Parsons et al. pessimistically 
advised against further clinical trials of cyclophosph-
amide.os 
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It is regrettable that these early efforts at renal 
transplantation under cyclophosphamide therapy were 
made when the conditions were not more propitious. 
Specifically, it was then believed that the deliberate 
production of leucopenia was desirable, whereas now 
we believe such a policy to be dangerous and un-
necessary. Moreover, as already implied, the im-
portance of combination drug therapy was not yet 
fully appreciated. We were able to use cyclophos-
phamide with two other potent immunosuppressants, 
prednisone and A.L.G., and against a background of 
considerable experience with multiple drug treatment. 
The impact that cyclophosphamide will have on 
clinical transplantation is still speculative, since few 
cases have been so managed and follow-up has been 
limited. At the least, however, cyclophosphamide is a 
potent drug to which one can turn if azathioprine 
therapy is stopped, as was demonstrated in the six 
patients with probable azathioprine hepatotoxicity 
described here. Moreover, it is conceivable that 
improvements in other aspects of routine immuno-
suppression may be possible using cyclophosphamide 
as a component of the triple-drug regimen (as described 
here), in combination with prednisone or A.L.G. 
alone, or in conjunction with azathioprine or other 
agents that have not yet been fully evaluated. 
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